^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib
Excerpt:
...All genders are permitted.- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.- Documented radiologic disease progression on first line osimertinib.- MET-amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.- Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional tissue for central testing which fulfils the following requirements: Obtained following progression on previous osimertinib therapy; obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. ...
Trial ID:
Source:
Title:
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico
Excerpt:
...- MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. ...
Trial ID:
More C2 evidence
Source:
Title:
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Excerpt:
...- MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment....
Trial ID:
Source:
Title:
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Excerpt:
...- MET amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment....
Trial ID:
Source:
Title:
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Excerpt:
...- MET high expression by IHC, 3+ in ≥75% of tumor cells...
Trial ID:
Less C2 evidence
Source:
Title:
Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC
Published date:
08/08/2023
Excerpt:
In a posthoc, exploratory analysis in the SAVANNAH clinical trial, QCS was performed on centrally stained MET IHC slides from patients treated with savolitinib 300mg QD + osimertinib 80mg QD (NCT03778229)….Improved efficacy in patients with high biomarker tumors (IHC90+ and/or FISH10+) as determined by manual score was recently reported (WCLC2022). Consistent with manual scores, patients with QCS derived BM+ tumors had a mPFS of 7.8m (95% CI: 5.8-10.4) compared to BM- tumors 2.9m (95%CI: 2.6-4.2)....In summary, we report the development and application of an image-analysis based computational pathology method for quantification of MET expression.
Trial ID:
